Yue Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Liu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hua Jiang
Department of Geriatrics, Shanghai East Hospital, Tongji University School of Medicine
2 shared publications - Huixiao Yuan
Department of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications - Jianli Ge
Department of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications - Qingqing Li
Department of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications - Shasha Geng
Department of General Practice, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China
2 shared publications - Xiaoli Wang
Pudong Institute for Health Development, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 20 December 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04263
Multimorbidity in elderly patients with or without T2DM: A real-world cross-sectional analysis based on primary care and hospitalisation data
Type 2 diabetes mellitus (T2DM) increases the global economic burden and risk of premature death [1]. Widespread use of medications such as aspirin and angiotensin-converting enzyme inhibitors (ACEIs) has progressively reduced the affected population’s risk of cardiovascular death and increased their life expectancy, leading to a higher likelihood of other age-related chronic diseases [2]. Many […]
- 20 December 2024
- Published by International Society of Global Health in Journal of Global Health
- Vol. 14, 04263
Open AccessMultimorbidity in elderly patients with or without T2DM: A real-world cross-sectional analysis based on primary care and hospitalisation data
Type 2 diabetes mellitus (T2DM) increases the global economic burden and risk of premature death [1]. Widespread use of medications such as aspirin and angiotensin-converting enzyme inhibitors (ACEIs) has progressively reduced the affected population’s risk of cardiovascular death and increased their life expectancy, leading to a higher likelihood of other age-related chronic diseases [2]. Many […]
- Open Access
- 13 November 2024
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (8) , 855-863
Nephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study
Objectives: This study aimed to investigate the nephroprotective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes mellitus (T2DM) and hypertension based on real-world clinical data. The study aimed to provide a theoretical basis for evidence-based pharmacological treatment of chronic kidney disease in this population. Methods: The 'Health Cloud' platform of the Shanghai Municipal Health Commission was employed to identify and screen elderly patients with T2DM and hypertension. The propensity score matching cohort was further constructed to estimate the effect of SGLT2i on the risk of rapid decline in renal function (triangle eGFR <=-5 ml/min/1.73 m(2) or triangle eGFR%<=-5%). Multiple sensitivity analyses were conducted to assess the robustness of the results. Results: After propensity score matching, no significant differences of covariates were identified between the SGLT2i and non-SGLT2i groups. The results of multivariate logistic models demonstrated a consistent and inverse correlation between SGLT2i use and the risk of rapid eGFR decline, whether defined as triangle eGFR <=-5 ml/min/1.73 m(2) (OR = 0.60, 95% CI:0.38-0.96) or triangle eGFR%<=-5%(OR = 0.57, 95% CI:0.37-0.89). In the stratification of renin-angiotensin system inhibitor (RASi) treatment, SGLT2i was associated with a lower risk of rapid eGFR decline in the RASi group (all ORs < 1, p < 0.05), with no interaction between SGLT2i and RASi (all P for interaction > 0.05) detected. Conclusions: SGLT2i significantly reduced the risk of rapid eGFR decline in elderly patients with T2DM and hypertension, but the synergistic effect with RASi remains unclear.
- 13 November 2024
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 136 (8) , 855-863
Open AccessNephroprotective effect of SGLT2 inhibitors in elderly patients with type 2 diabetes mellitus and hypertension: a real-world population-based cohort study
Objectives: This study aimed to investigate the nephroprotective effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in elderly patients with type 2 diabetes mellitus (T2DM) and hypertension based on real-world clinical data. The study aimed to provide a theoretical basis for evidence-based pharmacological treatment of chronic kidney disease in this population. Methods: The 'Health Cloud' platform of the Shanghai Municipal Health Commission was employed to identify and screen elderly patients with T2DM and hypertension. The propensity score matching cohort was further constructed to estimate the effect of SGLT2i on the risk of rapid decline in renal function (triangle eGFR <=-5 ml/min/1.73 m(2) or triangle eGFR%<=-5%). Multiple sensitivity analyses were conducted to assess the robustness of the results. Results: After propensity score matching, no significant differences of covariates were identified between the SGLT2i and non-SGLT2i groups. The results of multivariate logistic models demonstrated a consistent and inverse correlation between SGLT2i use and the risk of rapid eGFR decline, whether defined as triangle eGFR <=-5 ml/min/1.73 m(2) (OR = 0.60, 95% CI:0.38-0.96) or triangle eGFR%<=-5%(OR = 0.57, 95% CI:0.37-0.89). In the stratification of renin-angiotensin system inhibitor (RASi) treatment, SGLT2i was associated with a lower risk of rapid eGFR decline in the RASi group (all ORs < 1, p < 0.05), with no interaction between SGLT2i and RASi (all P for interaction > 0.05) detected. Conclusions: SGLT2i significantly reduced the risk of rapid eGFR decline in elderly patients with T2DM and hypertension, but the synergistic effect with RASi remains unclear.